The United Kingdom and the United States have secured a major trade agreement that will preserve zero tariffs on UK drug products being sold in the American market.
The Terms of the Deal
As part of the deal, the UK has agreed to raise funding on pharmaceuticals through the public health system. This pledge guarantees that duties on these vital goods will be held at zero for a duration of three years.
This deal follows previous warnings to significantly raise duties on patented drug products, with potential rates floated as high as double the cost.
"This deal between the United Kingdom reinforces the worldwide climate for innovative medicines and introduces much-needed equity to American-British drug exports," a statement noted.
Trade Significance
Pharmaceuticals represent one of the the United Kingdom's biggest exports to the America, which is by far the primary market for large companies like GSK and AstraZeneca.
Trade data indicate that in the one-year period prior to September, the UK exported medicines totaling over eleven billion pounds to the US. This figure made up nearly one-fifth of British export trade in that timeframe.
"This deal secures jobs, stimulates funding and facilitates the UK to become a global hub for biotech and pharma," a minister commented.
Detailed NHS Changes
The pact involves several specific changes from the United Kingdom:
- Price Threshold Increase: The UK will increase the affordability limit at which it deems new medicines to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a goal to increase total public funding on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The sum manufacturers must pay back to the NHS to stay within budget will be limited at fifteen percent. In the past, rebates were more than 20%.
Industry Background
This agreement comes amid a protracted tension between the sector and the UK government over spending levels and NHS adoption.
This friction were exacerbated by claims that American patients were paying significantly more for the equivalent treatments than patients in the UK and Europe.
Recently, several large drug company projects in the UK have been delayed or abandoned, while substantial expansions have been directed toward projects in the United States.
The Science Minister stated that the NHS must increase expenditure on medicines, noting that its expenditure on drugs had declined as a proportion of its overall budget over the past decade.
